1Neonatal Unit, St George's Hospital, London.
Respiratory syncytial virus (RSV) impacts most young children, posing risks to infants. Palivizumab, a new antibody, significantly lowers RSV hospitalizations in high-risk infants when given preventatively.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: